Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer (NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival rate for immunotherapy patients is 3-fold higher, approximately 4%–5% versus 15%–16%, respectively. Immunotherapies include...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Fuli Wang, Teng Xia, Zhiqiang Li, Xuzhu Gao, Xinjian Fang
Natura:	Articolo
Lingua:	English
Pubblicazione:	Frontiers Media S.A. 2023-09-01
Serie:	Frontiers in Oncology
Soggetti:	non-small cell lung cancer immune checkpoint inhibitors CTLA-4 PD-1 PD-L1
Accesso online:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1213297/full

Documenti analoghi

Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of  Small Cell Lung Cancer
di: Benlin HUANG, et al.
Pubblicazione: (2019-04-01)

Immune Checkpoint Inhibitors in Cancer Therapy
di: Yavar Shiravand, et al.
Pubblicazione: (2022-04-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
di: Ahmed M. Basudan
Pubblicazione: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
di: Gabriel Surdacki, et al.
Pubblicazione: (2019-03-01)

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
di: Shengjie Tang, et al.
Pubblicazione: (2022-01-01)

Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
di: Chengdi Wang, et al.
Pubblicazione: (2019-07-01)

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer
di: Jiahui He, et al.
Pubblicazione: (2023-03-01)

Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates
di: Suraya R, et al.
Pubblicazione: (2022-06-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
di: Adel Naimi, et al.
Pubblicazione: (2022-04-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
di: Deniz Can Guven, et al.
Pubblicazione: (2022-10-01)

Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review
di: Yu CW, et al.
Pubblicazione: (2020-11-01)

Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors
di: WANG Shuo, et al.
Pubblicazione: (2023-03-01)

An overview of immune checkpoint inhibitor toxicities in bladder cancer
di: Avenie Mavadia, et al.
Pubblicazione: (2024-12-01)

Immunotherapy in Extensive-Stage Small Cell Lung Cancer
di: Rola El Sayed, et al.
Pubblicazione: (2021-10-01)

Immune checkpoint inhibitors and prostate cancer: a new frontier?
di: Alessandra Modena, et al.
Pubblicazione: (2016-04-01)

Key questions about the checkpoint blockade-are microRNAs an answer?
di: Mihnea Dragomir, et al.
Pubblicazione: (2018-06-01)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
di: Shuai Wang, et al.
Pubblicazione: (2018-08-01)

Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
di: Gwenyth J. Joseph, et al.
Pubblicazione: (2023-12-01)

Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions
di: Kimberly M. Winges, et al.
Pubblicazione: (2022-11-01)

Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis
di: Dandan Song, et al.
Pubblicazione: (2024-11-01)

Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population‐based cohort study
di: Jeffrey Shi Kai Chan, et al.
Pubblicazione: (2023-04-01)

A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety
di: Nestor Rubio-Infante, et al.
Pubblicazione: (2022-03-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
di: Kübra KAHVECİ, et al.
Pubblicazione: (2019-12-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
di: Jing Huang, et al.
Pubblicazione: (2017-05-01)

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors
di: D. I. Yudin, et al.
Pubblicazione: (2020-07-01)

Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
di: Connor Frey, et al.
Pubblicazione: (2024-07-01)

Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events
di: Davies M, et al.
Pubblicazione: (2017-08-01)

Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for  Non-small Cell Lung Cancer
di: Sixuan WU, et al.
Pubblicazione: (2019-07-01)

Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition
di: Hans Urban, et al.
Pubblicazione: (2020-01-01)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
di: Yue Zhang, et al.
Pubblicazione: (2022-04-01)

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
di: Ming Yi, et al.
Pubblicazione: (2019-03-01)

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)
di: Caicun ZHOU, et al.
Pubblicazione: (2020-02-01)

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
di: Julie M. Collins, et al.
Pubblicazione: (2018-08-01)

Immune Checkpoints and Innovative Therapies in Glioblastoma
di: Massimo Romani, et al.
Pubblicazione: (2018-10-01)

Thyroid-related adverse events induced by immune checkpoint inhibitors
di: Alexandra Chera, et al.
Pubblicazione: (2022-09-01)

Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
di: Yinghong Zhai, et al.
Pubblicazione: (2019-11-01)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
di: Hanna Karhapää, et al.
Pubblicazione: (2022-02-01)

Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
di: Lijun Peng, et al.
Pubblicazione: (2022-09-01)

Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
di: Wonyoung Jo, et al.
Pubblicazione: (2024-02-01)

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
di: Jianmin Wu, et al.
Pubblicazione: (2021-06-01)